Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

Last Posted: Jun 04, 2017

---

• Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.  
  Hollis Robert L et al. OncoTargets and therapy 2017 2539-2551
• PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.  
  Evans Tarra et al. Therapeutic advances in medical oncology 2017 Apr (4) 253-267
• Phase III Trial of PARP Inhibitor Shows First Evidence of Improved Outcomes in Breast Cancer  
  Memorial Sloan Kettering, ASCO, June 4, 2017
• Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.  
  Cseh Anna Mária et al. Oncotarget 2017 Apr
• The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.  
  Martinez-Useros Javier et al. BioMed research international 2016 20161869304
• Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.  
  George Angela et al. Nature reviews. Clinical oncology 2016 Dec
• PARP Inhibitors in Ovarian Cancer Treatment  
  DR Spriggs et al,NEJM, November 30, 2016
• Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.  
  Badoer Cindy et al. Oncotarget 2016 Oct
• Novel BRCA1 and BRCA2 Tumour Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.  
  Weren Robbert D A et al. Human mutation 2016 Oct
• Precision medicine for advanced prostate cancer.  
  Mullane Stephanie A et al. Current opinion in urology 2016 May 26(3) 231-9
• The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.  
  Niravath Polly et al. JAMA oncology 2016 Aug
• The integration of BRCA testing into oncology clinics.  
  Percival Natalie et al. British journal of nursing (Mark Allen Publishing) 2016 Jun 25(12) 690-4
• Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.  
  Karakasis Katherine et al. Frontiers in oncology 2016 6119
• The development of PARP inhibitors in ovarian cancer: from bench to bedside.  
  Drew Yvette et al. British journal of cancer 2015 Dec S3-9
• Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.  
  Singer C F et al. Wiener klinische Wochenschrift 2015 Nov
• Excitement building for PARP inhibitors in BRCA-mutated breast cancer,  
  by Tony Hagen, OncLive, Feb 27